Gino Marioni1, Marco Agostini2, Rocco Cappellesso3, Chiara Bedin4, Giancarlo Ottaviano1, Rosario Marchese-Ragona1, Andrea Lovato1, Tommaso Cacco1, Luciano Giacomelli3, Donato Nitti5, Stella Blandamura3, Edoardo Stellini6, Cosimo de Filippis7. 1. Department of Neurosciences DNS, Otolaryngology Section, Padova University, Padova, Italy. 2. Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy Istituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy Nanomedicine Department, The Methodist Hospital Research Institute, Houston, Texas, USA. 3. Department of Medicine DIMED, University of Padova, Padova, Italy. 4. Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy Istituto di Ricerca Pediatrica-Città della Speranza, Padova, Italy. 5. Department of Surgical, Oncological and Gastroenterological Sciences, Padova University, Padova, Italy. 6. Department of Neurosciences DNS, Odontostomatology Institute, Padova University, Padova, Italy. 7. Department of Neurosciences DNS, Audiology Unit, Treviso Hospital, Padova University, Treviso, Italy.
Abstract
BACKGROUND: Laryngeal verrucous squamous cell carcinoma (VSCC) is a highly differentiated squamous cell carcinoma (SCC), the diagnosis of which can meet with many pitfalls: benign hyperplastic lesions and conventional SCC are the most important differential diagnoses. The microRNA miR-19a is overexpressed in many solid tumours and regulates the suppressor of cytokine signalling-1 (SOCS-1) expression. AIMS: The main endpoints were to assess miR-19a and SOCS-1 expression in glottic VSCC, and the former's potential role in differentiating between glottic VSCC, conventional SCC and hyperplastic lesions. METHODS: The expression of MiR-19a (by reverse transcription and quantitative real-time PCR) and SOCS-1 (by immunohistochemistry, rabbit polyclonal anti-SOCS-1 antibody) was assessed in 11 consecutive cases of glottic VSCC, 20 of papillary hyperplasia and 42 cases of conventional SCC. RESULTS: Mean miR-19a expression was significantly higher (p = 0.000) in malignant glottic lesions (conventional SCC/VSCC) than in benign conditions. Significant differences in mean miR-19a expression also emerged between conventional SCC and papillary hyperplasia (p = 0.000), and between conventional SCC and VSCC (p = 0.03). miR-19a expression was not statistically associated with SOCS-1 immunoreactivity or immunostaining intensity in VSCC, conventional SCC or papillary hyperplasia. CONCLUSIONS: Our preliminary outcomes suggest the utility of miR-19a in the challenging differential diagnosis of laryngeal VSCC. Although miR-19a has been found to regulate SOCS-1 expression, this evidence was not confirmed by this investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Laryngeal verrucous squamous cell carcinoma (VSCC) is a highly differentiated squamous cell carcinoma (SCC), the diagnosis of which can meet with many pitfalls: benign hyperplastic lesions and conventional SCC are the most important differential diagnoses. The microRNA miR-19a is overexpressed in many solid tumours and regulates the suppressor of cytokine signalling-1 (SOCS-1) expression. AIMS: The main endpoints were to assess miR-19a and SOCS-1 expression in glottic VSCC, and the former's potential role in differentiating between glottic VSCC, conventional SCC and hyperplastic lesions. METHODS: The expression of MiR-19a (by reverse transcription and quantitative real-time PCR) and SOCS-1 (by immunohistochemistry, rabbit polyclonal anti-SOCS-1 antibody) was assessed in 11 consecutive cases of glottic VSCC, 20 of papillary hyperplasia and 42 cases of conventional SCC. RESULTS: Mean miR-19a expression was significantly higher (p = 0.000) in malignant glottic lesions (conventional SCC/VSCC) than in benign conditions. Significant differences in mean miR-19a expression also emerged between conventional SCC and papillary hyperplasia (p = 0.000), and between conventional SCC and VSCC (p = 0.03). miR-19a expression was not statistically associated with SOCS-1 immunoreactivity or immunostaining intensity in VSCC, conventional SCC or papillary hyperplasia. CONCLUSIONS: Our preliminary outcomes suggest the utility of miR-19a in the challenging differential diagnosis of laryngeal VSCC. Although miR-19a has been found to regulate SOCS-1 expression, this evidence was not confirmed by this investigation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Miao Liu; Lingyao Du; Xing Cheng; Man Yuan; Jin Shang; Ying Shi; Hailing Yang; Hong Tang Journal: Front Microbiol Date: 2022-06-06 Impact factor: 6.064
Authors: F Ricciardiello; R Capasso; H Kawasaki; T Abate; F Oliva; A Lombardi; G Misso; D Ingrosso; C A Leone; M Iengo; M Caraglia Journal: Acta Otorhinolaryngol Ital Date: 2017-12 Impact factor: 2.124